Abstract
Patients with cancer receiving chemotherapy often have chemotherapy-induced anemia (CIA) and reduced quality of life. Darbepoetin alfa can effectively treat CIA when administered at an extended dosing interval of once every 3 weeks (Q3W). Darbepoetin alfa administered Q3W may allow synchronization of darbepoetin alfa therapy with chemotherapy administered Q3W. This multicenter, open-label, 16-week study evaluated the effectiveness and safety of darbepoetin alfa administered as a fixed dose (300 μg) Q3W in patients with CIA. Eligible patients (≥18 years) were anemic (hemoglobin
Original language | English (US) |
---|---|
Pages (from-to) | 409-417 |
Number of pages | 9 |
Journal | Oncologist |
Volume | 11 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2006 |
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research